Immune checkpoint inhibitors (ICIs) and BRAF/MEK kinase inhibitors have substantially improved survival in advanced melanoma; however, therapeutic resistance and severe toxicities underscore the ongoing need for alternative strategies. Here, we evaluate the clinical utility of multi-omic profiling, biomarker-stratified...
T. Lowinus, V. Schipperges, P. Metzger et al.· npj Precision Oncology· 0 citations
TAVR induces a coordinated thromboinflammatory response across systemic, cellular, and transcriptomic levels, characterized by systemic coagulation and inflammatory activation, platelet phenotypic alterations, and transcriptional enrichment of platelet activation pathways.
D. Hesselbarth, A. Hoelzle, S. Teegelbekkers et al.· European Heart Journal· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers with a five-year survival rate below 10%. Due to aggressiveness and lack of early detection methods, patients are often diagnosed at an advanced stage, leaving few therapeutic options. This emphasizes the need for a deeper understanding of the mo...
P. Winckler, Georg Vladimirov, Lennart Herrlich et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.